| 000 | 03599nlm1a2200517 4500 | ||
|---|---|---|---|
| 001 | 659611 | ||
| 005 | 20231030041635.0 | ||
| 035 | _a(RuTPU)RU\TPU\network\28278 | ||
| 035 | _aRU\TPU\network\19677 | ||
| 090 | _a659611 | ||
| 100 | _a20190311a2018 k y0engy50 ba | ||
| 101 | 0 | _aeng | |
| 135 | _adrcn ---uucaa | ||
| 181 | 0 | _ai | |
| 182 | 0 | _ab | |
| 200 | 1 |
_aPharmacogenetics of tardive dyskinesia in schizophrenia: The role of CHRM1 and CHRM2 muscarinic receptors _fA. S. Boyko [et al.] |
|
| 203 |
_aText _celectronic |
||
| 300 | _aTitle screen | ||
| 320 | _a[References: 33 tit.] | ||
| 330 | _aObjectives: Acetylcholine M (muscarinic) receptors are possibly involved in tardive dyskinesia (TD). The authors tried to verify this hypothesis by testing for possible associations between two muscarinic receptor genes (CHRM1 and CHRM2) polymorphisms and TD in patients with schizophrenia. Methods: A total of 472 patients with schizophrenia were recruited. TD was assessed cross-sectionally using the Abnormal Involuntary Movement Scale. Fourteen allelic variants of CHRM1 and CHRM2 were genotyped using Applied Biosystems amplifiers (USA) and the MassARRAY System by Agena Bioscience. Results: The prevalence of the rs1824024*GG genotype of the CHRM2 gene was lower in TD patients compared to the group without it (χ2 = 6.035, p = 0.049). This suggested that this genotype has a protective effect for the development of TD (OR = 0.4, 95% CI: 0.19-0.88). When age, gender, duration of schizophrenia and dosage of antipsychotic treatment were added as covariates in regression analysis, the results did not reach statistical significance. Conclusions: This study did identify associations between CHRM2 variations and TD; the results of logistic regression analysis with covariates suggest that the association is, however, likely to be secondary to other concomitant factors. | ||
| 461 | _tThe World Journal of Biological Psychiatry | ||
| 463 |
_tLatest Articles _v[7 p.] _d2018 |
||
| 610 | 1 | _aэлектронный ресурс | |
| 610 | 1 | _aтруды учёных ТПУ | |
| 610 | 1 | _atardive dyskinesia | |
| 610 | 1 | _amuscarinic acetylcholine receptors | |
| 610 | 1 | _apolymorphisms | |
| 610 | 1 | _apharmacogenetics | |
| 610 | 1 | _aschizophrenia | |
| 610 | 1 | _aшизофрения | |
| 610 | 1 | _aфармакогенетика | |
| 610 | 1 | _aполиморфия | |
| 701 | 1 |
_aBoyko _bA. S. _gAnastasiya Sergeevna |
|
| 701 | 1 |
_aIvanova _bS. A. _cspecialist in the field of ecology and life safety _cProfessor of Tomsk Polytechnic University, doctor of medical sciences _f1964- _gSvetlana Aleksandrovna _2stltpush _3(RuTPU)RU\TPU\pers\33859 |
|
| 701 | 1 |
_aPozhidaev _bI. V. _gIvan |
|
| 701 | 1 |
_aFreydin _bM. B. _gMaksim Borisovich |
|
| 701 | 1 |
_aOsmanova _bD. Z. _gDiana |
|
| 701 | 1 |
_aFedorenko _bO. Yu. _cspecialist in the field of ecology and life safety _cProfessor of Tomsk Polytechnic University, doctor of medical sciences _f1973- _gOlga Yurievna _2stltpush _3(RuTPU)RU\TPU\pers\33861 |
|
| 701 | 1 |
_aSemke _bA. V. |
|
| 701 | 1 |
_aBokhan _bN. |
|
| 701 | 1 |
_aWilffert _bB. _gBob |
|
| 701 | 1 |
_aLoonen _bA. J. M. _gAnton |
|
| 712 | 0 | 2 |
_aНациональный исследовательский Томский политехнический университет _bИнженерная школа неразрушающего контроля и безопасности _bОтделение контроля и диагностики _h7978 _2stltpush _3(RuTPU)RU\TPU\col\23584 |
| 801 | 2 |
_aRU _b63413507 _c20190311 _gRCR |
|
| 856 | 4 | _uhttps://doi.org/10.1080/15622975.2018.1548780 | |
| 942 | _cCF | ||